参考文献/References:
[1]Sung H,Ferlay J,Siegel RL,et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA Cancer J Clin,2021,71(3):209-249.[2]Lai W,Derek L,Cheuk-Ting L,et al.Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for sorafenib resistance in HCC[J].Nat Commun,2019,10(1):4681.[3]曾永毅,林孔英,唐世川.靶向联合免疫时代肝细胞癌转化治疗策略[J].中华消化外科杂志,2022,21(2):224-230.[4]Couri T,Pillai A.Goals and targets for personalized therapy for HCC[J].Hepatol Int,2019,13(2):125-137.[5]Ruiz M,Bodhicharla R,Svensk E,et al.Membrane fluidity is regulated by the C. elegans transmembrane protein FLD-1 and its human homologs TLCD1/2[J].Elife,2018,7:e40686.[6]Nicolson GL.Cell membrane fluid-mosaic structure and cancer metastasis[J].Cancer Res,2015,75(7):1169-1176.[7]Li Y,Yang X,Yang J,et al.An 11-gene-based prognostic signature for uveal melanoma metastasis based on gene expression and DNA methylation profile[J].J Cell Biochem,2019,120(5):8630-8639.[8]Vasaikar SV,Straub P,Wang J,et al.LinkedOmics: analyzing multi-omics data within and across 32 cancer types[J].Nucleic Acids Res,2018,46(D1):D956-D963.[9]Oulas A,Minadakis G,Zachariou M,et al.Systems Bioinformatics: increasing precision of computational diagnostics and therapeutics through network-based approaches[J].Brief Bioinform,2019,20(3):806-824.[10]刘淦,孙杰,张婷,等.晚期肝细胞癌靶向治疗及个性化治疗的现状[J].传染病信息,2019,32(2):103-108.[11]Faivre S,Rimassa L,Finn RS.Molecular therapies for HCC: Looking outside the box[J].J Hepatol,2020,72(2):342-352.[12]Bartel K,Winzi M,Ulrich M,et al.V-ATPase inhibition increases cancer cell stiffness and blocks membrane related Ras signaling - a new option for HCC therapy[J].Oncotarget,2017,8(6):9476-9487.[13]Lin L,Ding Y,Wang Y,et al.Functional lipidomics: Palmitic acid impairs hepatocellular carcinoma development by modulating membrane fluidity and glucose metabolism[J].Hepatology,2017,66(2):432-448.[14]Cunli G,Yumei B,Lei Z,et al.Microwaves as modulators of membrane stability parameters during hepatic cancer[J].J BUON,2019,24(1):158-162.[15]Long J,Wang A,Bai Y,et al.Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma[J].EBioMedicine,2019,42:363-374.[16]Khuda SE,Yoshida M,Xing Y,et al.The Sac3 homologue shd1 is involved in mitotic progression in mammalian cells[J].J Biol Chem,2004,279(44):46182-46190.[17]Han ME,Kim JY,Kim GH,et al.SAC3D1: a novel prognostic marker in hepatocellular carcinoma[J].Sci Rep,2018,8(1):15608.[18]Li N,Zhao L,Guo C,et al.Identification of a novel DNA repair-related prognostic signature predicting survival of patients with hepatocellular carcinoma[J].Cancer Manag Res,2019,11:7473-7484.[19]Calderaro J,Couchy G,Imbeaud S,et al.Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification[J].J Hepatol,2017,67(4):727-738.[20]Liu Z,Liu L,Guo C,et al.Tumor suppressor gene mutations correlate with prognosis and immunotherapy benefit in hepatocellular carcinoma[J].Int Immunopharmacol,2021,101(Pt B):108340.
相似文献/References:
[1]陈 旸,曾 川,张献全.肝细胞肝癌的靶向及免疫治疗研究现状与进展[J].医学信息,2019,32(03):45.[doi:10.3969/j.issn.1006-1959.2019.03.015]
CHEN Yang,ZENG Chuan,ZHANG Xian-quan.Current Status and Progress of Research on Hepatocellular Carcinoma Targeting and Immunotherapy[J].Journal of Medical Information,2019,32(04):45.[doi:10.3969/j.issn.1006-1959.2019.03.015]
[2]袁国辉,戴 超,吴兆平,等.CyclinA2基因多态性与肝细胞肝癌易感性的关系[J].医学信息,2018,31(22):77.[doi:10.3969/j.issn.1006-1959.2018.22.021]
YUAN Guo-hui,DAI Chao,WU Zhao-ping,et al.Relationship between Polymorphism of CyclinA2 Gene and Susceptibility to Hepatocellular Carcinoma[J].Journal of Medical Information,2018,31(04):77.[doi:10.3969/j.issn.1006-1959.2018.22.021]